FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

Colgate-Palmolive

CLConsumer Staples

Generated Aug 19, 2026, 10:30 PM UTC

analytical score -2

CL (Colgate-Palmolive) analytical snapshot. Revenue grew +1.4% YoY to $20.38B. 5-year revenue CAGR +3.2%; 10y CAGR +3.3%. Net margin at 10.46% (expanding ▲). Market cap $72.44B at $90.87 per share. Trailing P/E 34.55, P/S 3.55, P/B 306.95. EV/Operating income ≈ 23.87 (EV $78.91B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -2 (data confidence 84%). Descriptive analytics from public filings — not investment advice.

Market cap
$72.44B
797.17M shares
Price
$90.87
NYQ
P/E (ttm)
34.55
Revenue (FY)
$20.38B
YoY +1.4%
Net margin
10.46%
▲ 0.53pp
Free cash flow
$3.63B
17.83% margin
Risk level
Elevated

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 20Improving
80% conf

Latest annual report (10-K) filed Feb 23, 2026. Latest quarterly report (10-Q) filed Jul 31, 2026. 12 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 23, 2026.
  • Latest quarterly report (10-Q) filed Jul 31, 2026.
  • 12 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference Colgate-Palmolive; broad institutional reporting.
  • Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
Latest 10-K
Feb 23, 2026
Annual report
Latest 10-Q
Jul 31, 2026
8-K (recent)
12
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRAug 9, 2002
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRNov 2, 2001
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRFeb 12, 2004
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRFeb 1, 2002
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA13F-HRMay 15, 2003
Recent 8-K material events
DateFormDescription
Jul 31, 20268-K8-K
May 13, 20268-K8-K
May 1, 20268-K8-K
Apr 9, 20268-K8-K
Mar 17, 20268-K8-K
Mar 12, 20268-K8-K
Jan 30, 20268-K8-K
Nov 10, 20258-KFORM 8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score 3Stable
72% conf

1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.

  • Operating cash flow exceeds net income: OCF is 1.97x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
Revenue
$20.38B
+1.4% YoY
Gross profit
$12.25B
+0.7% YoY
Operating income
$3.31B
-22.5% YoY
Net income
$2.13B
-26.2% YoY
Operating cash flow
$4.20B
+2.2% YoY
Capex
$564.0M
+0.5% YoY
Total assets
$16.33B
+1.8% YoY
Total liabilities
$15.96B
+3.0% YoY
Filing quality score
72/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$20.10B$20.38B$281.0M+1.4%
Gross profit$12.16B$12.25B$90.0M+0.7%
Operating income$4.27B$3.31B$-962.0M-22.5%
Net income$2.89B$2.13B$-757.0M-26.2%
Operating cash flow$4.11B$4.20B$91.0M+2.2%
Capex$561.0M$564.0M$3.0M+0.5%
Total assets$16.05B$16.33B$284.0M+1.8%
Total liabilities$15.50B$15.96B$463.0M+3.0%
Long-term debt$7.00B$7.84B$834.0M+11.9%
Cash & equivalents$1.10B$1.29B$192.0M+17.5%
Stockholders equity$212.0M$54.0M$-158.0M-74.5%
Inventory$1.99B$2.03B$45.0M+2.3%
Accounts receivable$1.52B$1.68B$154.0M+10.1%
R&D expense$355.0M$366.0M$11.0M+3.1%
SG&A expense$7.73B$7.90B$174.0M+2.3%
Interest expense$172.0M$299.0M$127.0M+73.8%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedSupplierFinanceProgramObligation
RemovedAccrualForTaxesOtherThanIncomeTaxesCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, CommitmentsAndContingencies, CommonStockSharesOutstanding, DeferredIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities, DeferredOtherTaxExpenseBenefit
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Impairment chargemedium56Ongoing
Restructuringmedium59Ongoing
Off-balance sheet arrangementsmedium52Ongoing
Related party transactionslow11Ongoing
Filing signal breakdown
Red flags: 0
Positive: 1
Watch: 0
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score 15Stable
80% conf

Revenue grew +1.4% YoY to $20.38B. 5-year revenue CAGR +3.2%; 10y CAGR +3.3%. Net margin at 10.46% (expanding ▲).

  • Revenue grew +1.4% YoY to $20.38B.
  • 5-year revenue CAGR +3.2%; 10y CAGR +3.3%.
  • Net margin at 10.46% (expanding ▲).
  • Return on equity 3948.15%, ROA 13.06%, ROIC 41.89%.
  • Gross margin 60.11%, operating margin 16.22%.
  • Free cash flow margin 17.83% ($3.63B).
  • Net income down ▼ +26.2% YoY.
  • Debt/equity 33.22, current ratio 1.03, net debt $6.47B.
  • Asset turnover 1.21 — capital efficiency.
Revenue (FY)
$20.38B
YoY +1.4%
Net margin
10.46%
▲ 0.53pp
ROE
3948.15%
ROA 13.06%
ROIC
41.89%
EPS (diluted)
$2.63
FY2025
Free cash flow
$3.63B
17.83% margin
Debt / equity
33.22
Cash $1.37B
Current ratio
1.03
Equity $236.0M
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$20.10B+3.3%60.5021.2314.37$3.55B1362.74
2025$20.38B+1.4%60.1116.2210.46$3.63B3948.15
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Jun 30, 2016$3.85B-5.4%—15.60%
Sep 30, 2016$3.87B-3.3%+0.6%18.15%
Mar 31, 2017$3.76B0.0%-2.7%15.15%
Jun 30, 2017$3.83B-0.5%+1.7%13.70%
Sep 30, 2017$3.97B+2.8%+3.9%15.27%
Mar 31, 2018$4.00B+6.4%+0.7%15.84%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -40Deteriorating
95% conf

Market cap $72.44B at $90.87 per share. Trailing P/E 34.55, P/S 3.55, P/B 306.95. EV/Operating income ≈ 23.87 (EV $78.91B).

  • Market cap $72.44B at $90.87 per share.
Market cap
$72.44B
797.17M shares
P/E (ttm)
34.55
P/S
3.55
P/B
306.95
EV
$78.91B
Intrinsic (DCF)
$78.42
-13.7% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score 15Stable
85% conf

Price $90.87 — uptrend (above 200-DMA); 1-month momentum negative. RSI(14) 46.91.

  • Price $90.87 — uptrend (above 200-DMA); 1-month momentum negative.
Price
$90.87
NYQ
RSI(14)
46.91
50-DMA
$91.62
200-DMA
$86.88
Volatility (ann.)
22.56%
52w range
$74.55–$99.33
-8.5% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score -20Deteriorating
90% conf

Composite risk Elevated. Leverage debt/equity 33.22 (high). Liquidity current ratio 1.03 (adequate).

  • Composite risk: Elevated.
Risk level
Elevated
Debt / equity
33.22
Current ratio
1.03
Margin stdev
2.08pp
Cash / assets
8.16%
Liab / assets
96.63%
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite -2

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. Colgate-Palmolive is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Market regime: Risk-on · Supportive..

Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How CL stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM21Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
HCA Healthcare HCA9Neutral
Gilead Sciences GILD8Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG7Neutral
Coca-Cola Co. KO6Neutral
Zoetis Inc. ZTS6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Illumina Inc. ILMN0Neutral
Colgate-Palmolive CL● you-2Neutral
Vertex Pharmaceuticals VRTX-2Neutral
AbbVie Inc. ABBV-5Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-12Neutral
Costco Wholesale COST-14Neutral
Walmart Inc. WMT-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral